Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
Sign Up to like & getrecommendations! Published in 2019 at "Pharmacoeconomics"
DOI: 10.1007/s40273-019-00806-4
Abstract: BackgroundStandard parametric survival models are commonly used to estimate long-term survival in oncology health technology assessments; however, they can inadequately represent the complex pattern of hazard functions or underlying mechanism of action (MoA) of immuno-oncology… read more here.
Keywords: estimating lifetime; immuno oncology; overall survival; oncology ... See more keywords